Apolipoprotein(a) size polymorphism is associated with coronary heart disease in polygenic hypercholesterolemia

E. Emanuele, E. Peros, P. Minoretti, A. D'Angelo, M. N. Piccinni, L. Montagna, D. Geroldi

Research output: Contribution to journalArticle


Background and Aim: In addition to high serum cholesterol levels, various cardiovascular risk factors may be involved in the development of coronary heart disease (CHD) in hypercholesterolemic subjects. As the levels of lipoprotein(a) [Lp(a)], an important and independent cardiovascular risk factor, are high in polygenic hypercholesterolemia (PH), we investigated plasma Lp(a) levels and apolipoprotein(a) [apo(a)] phenotypes in relation to occurrence of CHD events in PH patients. Methods and Results: Lp(a) levels and apo(a) isoforms were determined in 191 PH patients, 83 normocholesterolemic subjects with CHD, and 94 normocholesterolemic controls without CHD. Lp(a) levels were similar in the hypercholesterolemic subjects with (n=100) or without CHD (n=91): 21.4 (range 6.6-59.23) vs 18.5 (range 5.25-57.25) mg/dL (p=NS). Low molecular weight apo(a) isoforms were more prevalent (55%) in the PH patients with CHD, whereas high molecular weight apo(a) isoforms were more prevalent (62.6%) in those without CHD: this difference was significant (p

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalNutrition, Metabolism and Cardiovascular Diseases
Issue number4
Publication statusPublished - Aug 2004



  • Apolipoprotein(a)
  • Coronary heart disease
  • Genetic markers
  • Lipoprotein(a)
  • Polygenic hypercholesterolemia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine (miscellaneous)
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this